Similarly, the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) trial, which evaluates EGFR, mTOR/DNA-PK, and CDK4/6 inhibitors [54], and the GBM Adaptive, Global, Innovative Learning Environment (AGILE) consortium [55], randomise patients into different arms of treatments based on the presence of biomarkers and may suggest a benefit from a specific targeted therapy. The gene discussed is MTOR; the disease is glioblastoma.